IRX Therapeutics’ Board of Directors announce new Senior Management hires

We exploit dislocations in markets and unlock value from complex situations using a Get Rich and Stay Rich strategy. This strategy has given rise to returns over 23 years of 28% p.a. Net IRR

IRX Therapeutics’ Board of Directors announce new Senior Management hires

 

IRX Therapeutics, a clinical-stage company developing novel immunotherapies focused on reducing immune suppression seen in the cancer tumour micro-environment, has announced two major hires in the senior management team.

 

Mark Leuchtenberger has been appointed as President, Chief Executive Officer and Director, while Monil Shah takes the position of Chief Operating Officer. One of the first tasks of the new President, CEO and Director was to present at the BioCentury 24th Annual Future Leaders in the Biotech Industry Conference in New York City on April 7th, 2017. Previous CEO and founder of IRX John W. Hadden II will continue as Director.

 

Mr. Leuchtenberger brings 20 years of experience as a senior executive in the biopharmaceutical industry where he has led companied through private financings and initial public offerings, taken products from IND through to commercialization and achieved M&A exits. He has served as President and Chief Executive Officer of companies such as Chiasma, Acusphere, Inc., and Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics Inc.). Mr. Leuchtenberger served as President and Chief Executive Officer of Targanta Therapeutics Corporation, where he led the company’s initial public offering in 2007 and its acquisition by The Medicines Company in 2009. Mr. Leuchtenberger served as the President and Chief Executive Officer of cancer vaccine company, Therion Biologics Corporation.

 

Dr. Shah brings a similar wealth of experience through 17 years of pharmaceutical and biotechnology industry experience in Oncology drug development, including Clinical Research and Development and Medical Affairs. Most recently, Dr. Shah was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb. Dr. Shah helped start a biotech company as the Head of Clinical Operations and Development at Ventrus Biosciences. Prior to Ventrus, Dr. Shah led the solid tumour development programs and was eventually offered the opportunity to lead the clinical portfolio and strategic planning function at Celgene Corporation.

 

For more information on IRX Therapeutics, see http://irxtherapeutics.com

News from Disruptive Capital Finance